3Spine Lumbar Fusion Real World Evidence Study

Inclusion Criteria: 1. Male or female, age 21-80 (inclusive) with at least 3 years of life expectancy; 2. Subject plans to undergo a one-level Open or Mini-Open TLIF or PLIF procedure (stabilized with pedicle screws) independent of this research protocol; 3. Subject is to be treated with on-label use of an FDA-cleared TLIF or PLIF cage(s) and pedicle screw system independent of this research protocol; 4. The subject has a primary diagnosis of symptomatic lumbar degeneration with or without foraminal or recess stenosis of the lumbar spine at a single level from L1/L2 to L5/S1 confirmed by subject history and radiographic imaging (CT, MRI, X-rays) with no more than a Grade 1 (\<25% translation) spondylolisthesis. Symptomatic lumbar degeneration that may be associated with a co-morbid condition such as: 1. Herniated nucleus pulposus; 2. Scarring/thickening of the ligamentum flavum, annulus fibrosus, or facet joint capsule; 3. Facet joint degeneration/osteophyte formation; 4. Spondylosis (defined by the presence of osteophytes); 5. Disc degeneration and/or annular degeneration; and/or 6. Lumbar stenosis defined by spinal cord or nerve root compression; 5. Exhausted conservative treatment (e.g. bed rest, physical therapy, medications, transcutaneous electrical nerve stimulation (TENS), manipulation, and/or spinal injections) for at least 3 months or has a neurologic emergency; 6. Preoperative Oswestry Disability Index score \>/= 40/100 at baseline; 7. Psychosocially, mentally and physically able and willing to fully comply with this protocol including adhering to follow-up schedule and requirements and filling out forms; and 8. Signed informed consent. Exclusion Criteria: 1. More than one vertebral level requiring treatment; 2. Previous instrumented surgery (i.e.: anterior disc replacement, spinal fusion, interspinous device, etc.) at the index lumbar level or an adjacent level; 3. Degenerative or lytic spondylolisthesis greater than Grade 1 (\<25% translation); 4. Rotatory scoliosis at the level to be treated; 5. Congenital bony and/or spinal cord abnormalities at the level to be treated; 6. Subcaudal defect, disrupting the integrity of the pedicle; 7. Clinically compromised vertebral bodies at the involved level due to current or past trauma, e.g., by the radiographic appearance of the fracture callus, malunion or nonunion; 8. Disrupted anterior longitudinal ligament at the index level; 9. Overlying thoracolumbar kyphosis (greater than or equal to 15 degrees) within one level (includes target and adjacent level) of the level to be treated; 10. Back pain of unknown etiology without leg pain; 11. Severe spondylosis at the level to be treated as characterized by any of the following: 1. Autofusion (solid arthrodesis) determined radiographically (CT); 2. Totally collapsed disc, or; 3. Vertebral body that cannot be mobilized; 12. Known allergy to cobalt, chromium, molybdenum, nickel, polyethylene, titanium, or vitamin E; 13. Unable to undergo a CT scan or other radiograph assessments; 14. Osteopenia: The SCORE/MORES will be utilized for all females age \<50 and males age \<55 to screen if a DEXA scan is indicated. If SCORE/MORES value ≥ 6, then a DEXA scan is required. A DEXA scan is indicated for all females age ≥50 and all males age ≥55. If DEXA is required, exclusion will be defined as a DEXA bone density measured T score ≤ -1. An existing DEXA is allowed if completed within 6 months of subject screening; 15. Has history of any endocrine or metabolic disorder known to affect osteogenesis (e.g.: Paget's disease, renal osteodystrophy, Ehler-Danlos syndrome, or osteogenesis imperfecta); 16. Insulin-dependent diabetes mellitus; 17. Lactating, pregnant or interested in becoming pregnant in the next 3 years; 18. Active infection - systemic or local; 19. Any medical condition requiring treatment with any drug known to potentially interfere with bone/soft tissue healing or receiving radiation therapy that is expected to continue for the duration of the study; 20. Body Mass Index \> 40; 21. Recurrent history of deep vein thrombosis, symptoms of arterial insufficiency, or thromboembolic disease; 22. Systemic disease including Lupus disease, Reiter's disease, Rheumatoid disease, AIDS, HIV, hepatitis or autoimmune disease that requires immunosuppressive therapy, including biologics, for systemic inflammation; 23. Spinal tumor; 24. Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years; 25. Any degenerative muscular or neurological condition that would interfere with evaluation of outcomes, including but not limited to Parkinson's disease, amyotrophic lateral sclerosis (ALS), or multiple sclerosis; 26. Has chronic or acute renal and/or hepatic impairment and/or failure or prior history of renal and/or hepatic parenchymal disease; 27. Has a Waddell Signs of Inorganic Behavior score of 3 or greater; 28. In the opinion of the investigator, the subject has a behavioral, cognitive, social or medical problem that may interfere with the assessment of the safety or effectiveness of the device; 29. Current or recent history of chemical/alcohol abuse or dependency using standard medical definition of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) code; 30. Currently smoking or using tobacco products, including e-cigarette products (e.g., vaping); (Use within 30 days of surgery date is considered 'current'); 31. Currently pursuing or in active spinal litigation for medical negligence, or trauma, or workers compensation; 32. Is a prisoner, incarcerated, or has been coerced to participate in the study that could impact the validity of results; 33. Is currently participating in an investigational therapy (device and/or pharmaceutical) within 30 days prior to entering the study or such treatment is planned during the 24 months following enrollment into the study.